4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Fundamental Analysis
USA - NASDAQ:FDMT - US35104E1001 - Common Stock
11.34 USD
+1.34 (+13.4%)
11.9 USD
+0.56 (+4.94%)
FDMT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for FDMT as it has an excellent financial health rating, but there are worries on the profitability. FDMT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year FDMT has reported negative net income.
FDMT had a negative operating cash flow in the past year.
In the past 5 years FDMT always reported negative net income.
FDMT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
FDMT's Return On Assets of -41.41% is in line compared to the rest of the industry. FDMT outperforms 58.43% of its industry peers.
FDMT has a better Return On Equity (-46.60%) than 68.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.41% | ||
| ROE | -46.6% | ||
| ROIC | N/A |
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for FDMT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FDMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FDMT has been increased compared to 1 year ago.
FDMT has more shares outstanding than it did 5 years ago.
FDMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
FDMT has an Altman-Z score of 3.16. This indicates that FDMT is financially healthy and has little risk of bankruptcy at the moment.
FDMT has a Altman-Z score of 3.16. This is in the better half of the industry: FDMT outperforms 69.29% of its industry peers.
There is no outstanding debt for FDMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.16 |
ROIC/WACCN/A
WACC8.66%
2.3 Liquidity
A Current Ratio of 8.75 indicates that FDMT has no problem at all paying its short term obligations.
FDMT has a Current ratio of 8.75. This is in the better half of the industry: FDMT outperforms 76.97% of its industry peers.
FDMT has a Quick Ratio of 8.75. This indicates that FDMT is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.75, FDMT is doing good in the industry, outperforming 76.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.75 | ||
| Quick Ratio | 8.75 |
3. Growth
3.1 Past
The earnings per share for FDMT have decreased strongly by -54.82% in the last year.
The Revenue for FDMT has decreased by -99.92% in the past year. This is quite bad
The Revenue for FDMT have been decreasing by -64.95% on average. This is quite bad
EPS 1Y (TTM)-54.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.56%
Revenue 1Y (TTM)-99.92%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%200%
3.2 Future
Based on estimates for the next years, FDMT will show a decrease in Earnings Per Share. The EPS will decrease by -7.85% on average per year.
FDMT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 130.91% yearly.
EPS Next Y-26.44%
EPS Next 2Y-13.7%
EPS Next 3Y-10.64%
EPS Next 5Y-7.85%
Revenue Next Year131.11%
Revenue Next 2Y47.6%
Revenue Next 3Y40.14%
Revenue Next 5Y130.91%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FDMT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FDMT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as FDMT's earnings are expected to decrease with -10.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.7%
EPS Next 3Y-10.64%
5. Dividend
5.1 Amount
FDMT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.34
+1.34 (+13.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners86.98%
Inst Owner Change-0.08%
Ins Owners3.85%
Ins Owner Change-0.22%
Market Cap529.58M
Revenue(TTM)33.00K
Net Income(TTM)-196144000
Analysts81.25
Price Target31.04 (173.72%)
Short Float %10.01%
Short Ratio6.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.75%
Min EPS beat(2)-9.71%
Max EPS beat(2)2.21%
EPS beat(4)1
Avg EPS beat(4)-6.46%
Min EPS beat(4)-10.47%
Max EPS beat(4)2.21%
EPS beat(8)5
Avg EPS beat(8)7.58%
EPS beat(12)8
Avg EPS beat(12)6.75%
EPS beat(16)11
Avg EPS beat(16)5.29%
Revenue beat(2)0
Avg Revenue beat(2)-96.24%
Min Revenue beat(2)-96.41%
Max Revenue beat(2)-96.07%
Revenue beat(4)0
Avg Revenue beat(4)-97.97%
Min Revenue beat(4)-99.94%
Max Revenue beat(4)-96.07%
Revenue beat(8)2
Avg Revenue beat(8)55.45%
Revenue beat(12)2
Avg Revenue beat(12)16.36%
Revenue beat(16)4
Avg Revenue beat(16)46.83%
PT rev (1m)5.74%
PT rev (3m)2.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22.91%
Revenue NY rev (1m)12.5%
Revenue NY rev (3m)-16.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 16047.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.26 | ||
| P/tB | 1.26 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.53
EYN/A
EPS(NY)-3.85
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.56
OCFYN/A
SpS0
BVpS9.01
TBVpS9.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.41% | ||
| ROE | -46.6% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.91% | ||
| Cap/Sales | 10375.8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.75 | ||
| Quick Ratio | 8.75 | ||
| Altman-Z | 3.16 |
F-Score2
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)195.17%
Cap/Depr(5y)250.86%
Cap/Sales(3y)3538.16%
Cap/Sales(5y)2134.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.56%
EPS Next Y-26.44%
EPS Next 2Y-13.7%
EPS Next 3Y-10.64%
EPS Next 5Y-7.85%
Revenue 1Y (TTM)-99.92%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%200%
Revenue Next Year131.11%
Revenue Next 2Y47.6%
Revenue Next 3Y40.14%
Revenue Next 5Y130.91%
EBIT growth 1Y-6.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.11%
EBIT Next 3Y-20.55%
EBIT Next 5YN/A
FCF growth 1Y-73.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.51%
OCF growth 3YN/A
OCF growth 5YN/A
4D MOLECULAR THERAPEUTICS IN / FDMT FAQ
What is the fundamental rating for FDMT stock?
ChartMill assigns a fundamental rating of 3 / 10 to FDMT.
Can you provide the valuation status for 4D MOLECULAR THERAPEUTICS IN?
ChartMill assigns a valuation rating of 0 / 10 to 4D MOLECULAR THERAPEUTICS IN (FDMT). This can be considered as Overvalued.
How profitable is 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?
4D MOLECULAR THERAPEUTICS IN (FDMT) has a profitability rating of 1 / 10.